Business Context and Reporting Period
Company: Ionis Pharmaceuticals, Inc. (IONS)
Filing Type: Form 8-K (Current Report)
Report Date: February 25, 2026
Reporting Period: Quarter and fiscal year ended December 31, 2025
This filing announces the issuance of a press release detailing financial results for the period ended December 31, 2025. The report includes both GAAP and non-GAAP (pro forma) results, with the latter excluding non-cash compensation expense and related tax effects to aid in performance assessment.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached press release (Exhibit 99.1) referenced in the document but are not explicitly stated in the 8-K text itself.
Material Changes
Comparison to Prior Period: The filing text does not provide specific data points or percentage changes comparing the current period to prior comparable periods. It only confirms that results for the quarter and fiscal year ended December 31, 2025, have been announced.
Guidance, Outlook, and Risks
Management Commentary: Management states that non-GAAP measures are presented to better enable users to assess historical performance and project future operating results and cash flows by excluding non-cash compensation expenses.
Guidance and Outlook: No specific forward-looking guidance or outlook figures are provided in this text.
Risks and Contingencies: The filing includes standard legal disclaimers stating that the information in the 8-K and its exhibits shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to incorporation by reference in other filings.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific GAAP and non-GAAP financial figures.
- Verify the exact amounts of non-cash compensation expense excluded from the pro forma results.
- Confirm the specific revenue and net income figures for the quarter and full year ended December 31, 2025.
- Check for any updated clinical trial milestones or regulatory approvals mentioned in the full press release.